Is Vimta Labs overvalued or undervalued?

As of 27 June 2025, the valuation grade for Vimta Labs has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 31.91, an EV to EBITDA ratio of 17.06, and a PEG ratio of 0.64, indicating a reasonable growth expectation relative to its price.
In comparison to its peers, Vimta Labs stands out against Poly Medicure, which is very expensive with a PE ratio of 64.67, and Blue Jet Health, also very expensive at a PE of 49.28. Notably, Vimta Labs has a return on capital employed (ROCE) of 24.24% and a return on equity (ROE) of 17.82%, which are strong indicators of its operational efficiency. While the stock has underperformed the Sensex in the short term, its impressive long-term returns of 883.72% over five years suggest strong underlying growth potential.